Retatrutide
- gqahhar
- Feb 2
- 1 min read
✨ Retatrutide: The Next Evolution in Weight Loss Medications ✨
You may be hearing the informal term “GLP-3” — but what does that actually mean?
Retatrutide is a new triple-agonist medication that targets three key hormones involved in metabolism and appetite:
• GLP-1
• GIP (glucose-dependent insulinotropic polypeptide)
• Glucagon
The most advanced example of this new class is retatrutide by Eli Lilly, based on current clinical trial outcomes.
💡 How it’s different from traditional GLP-1s:
Most medications like semaglutide only mimic one hormone (GLP-1).
Retatrutide mimics three hormones, which may lead to greater results.
🔬 How it works in the body:
• GLP-1 + GIP help the pancreas release insulin after meals
• They slow digestion → helping you feel fuller longer
• They act on the brain’s appetite center → reducing cravings
• Glucagon boosts metabolism and helps the body burn stored fat for energy
• The balance of all three helps prevent blood sugar spikes
📊 Clinical trial outcomes so far:
Participants experienced 24–28% average weight loss from starting body weight.
📅 What’s next:
Seven additional Phase 3 trials are expected to finish in 2026
Potential FDA approval as early as 2027
This could be a game-changer in the future of obesity and metabolic care. 🧬✨
Comments